Varex Imaging Corporation
Varex Imaging Corporation Q3 FY2025 earnings call
August 8, 2025 · fiscal period ended 2025-06
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2025-08-08
Management highlights
- Revenue of $203 million was above the high end of guidance; non-GAAP gross margin was 34%, above guidance. - Chinese customers paused shipments due to high tariffs but resumed once tariffs dropped, and Varex accommodated their needs. - Medical segment progress: India expansion plans, LUMEN HD detectors launched with regulatory approvals, photon counting with OEMs and new product THOR for industrial CT. - Industrial segment: Cargo systems performing well, new orders for cargo inspection systems, vertical integration advantage. - Paid off $200 million convertible notes, ended quarter with $153 million in cash, adjusted EBITDA $29 million for the quarter.
Segment performance
Total revenue was $203 million in the third quarter. The Medical segment had revenue of $142 million (70% of total revenues) and decreased 4% year-over-year. The Industrial segment had revenue of $61 million (30% of total revenues) and increased 1% year-over-year. China sales contributed 15% of total revenues, increased 4% year-over-year, and ended up fairly in line with recent quarters.
Guidance
- Fourth quarter revenues expected between $210 million and $230 million. - Non-GAAP earnings per diluted share expected between $0.10 and $0.30. - Non-GAAP gross margin expected 32%-33%, non-GAAP operating expenses ~$51 million, interest and other expense net $9M-$10M, tax rate ~25%.
Risks
- Tariffs: Fluctuations in tariffs affected shipments and margins. - Supply Chain: Dependence on global supply chains and potential disruptions. - Regulatory: Changes in regulatory requirements impacting product approvals and sales.
Q&A highlights
Q: Could you fulfill orders to China and did it cause higher expenses?
A: Sunny Sanyal said no, they had capacity and fulfilled demand without extra expenses.
Q: Expectations for China sales in Q4?
A: Sam Maheshwari said demand in China is stable and healthy, expected to remain normal.
Q: Photon counting in medical OEMs?
A: Sunny Sanyal said there are big CT projects on medical side with OEMs in design implementation phase.
Q: China business and government stimulus impact?
A: Sunny Sanyal said sales in China steady, no lumpy buying, and no significant impact from government stimulus yet.
Q: Gross margin outlook and mix?
A: Shubham Maheshwari said gross margin degradation due to tariffs and cargo systems mix, with service margins improving over time.
Q: Supply chain redirect for tariffs?
A: Sunny Sanyal said making progress with initiatives like India production, bonded warehouses, and passing price increases, but takes time.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | — | — | — | — |
| Revenue | — | — | — | — |
Transcript
August 8, 2025Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.